Pfizer Inc. (PFE)[Tv]

Key Developments

• FDA approval of Padcev (enfortumab vedotin) for muscle-invasive bladder cancer regardless of cisplatin eligibility — This landmark regulatory milestone significantly expands Padcev’s commercial footprint, directly fueling a 23% sales surge and solidifying Pfizer’s oncology leadership in a high-growth therapeutic area.
• FDA approval of Ibrance (palbociclib) in combination with AstraZeneca’s camizestrant for advanced HR-positive, HER2-negative breast cancer — A pivotal near-term catalyst that reaffirms PFE’s oncology strategy and delivers a strong revenue boost in a high-value segment, despite the setback in the SERENA-4 trial.
• FDA expanded approval of XFG-adapted COMIRNATY mRNA vaccine for the 2026–2027 season — Reinforces Pfizer’s enduring leadership in mRNA technology and provides a stable, high-margin revenue stream amid post-pandemic normalization, though market reach is limited to adults 65+ and high-risk patients under 65.
• EMA validation of Pfizer’s Lyme disease vaccine candidate, PF-07307405 — Marks a transformative milestone as the potential first-ever Lyme vaccine in Europe and North America, validating Pfizer’s next-generation preventive biologics platform and expanding its infectious disease footprint.
• Pfizer’s inclusion in the Trump administration’s "most favored nation" (MFN) pricing initiative — A game-changing regulatory shift requiring participation in new drug pricing deals, $19.6B in domestic manufacturing investments, and API donations, posing severe financial and strategic uncertainty.